Cardiff Oncology Shares Pop After Lead Asset Data In KRAS-Mutated Colorectal Cancer

  • Clinical-stage biotech Cardiff Oncology Inc CRDF announced new preclinical and clinical data from its lead program in KRAS-mutated metastatic colorectal carcinoma (mCRC) in a second-line setup. 
  • The data featured in a presentation at the European Society for Medical Oncology (ESMO) Congress 2022 included updated data and biomarker analyses from Phase 1b/2 trial for onvansertib plus chemotherapy FOLFIRI and cancer therapy bevacizumab.
  • As of July 26 data cutoff, overall response rate (ORR) and median progression-free survival (mPFS) significantly surpassed those in historical control studies.
  • Related: Cardiff Oncology Slumps On New Data From Lead Program In Metastatic Colorectal Cancer.
  • In an analysis of clinical responses, the KRAS responder group had greater ORR and mPFS than non-responders.
  • Another ESMO presentation discussed a comparison between KRAS responders and non-responders in CRDF’s Expanded Access Program, which included patients who were ineligible to participate in the Phase 1b/2 trial.
  • As of August 5, EAP patients who had received colorectal cancer therapy irinotecan demonstrated clinical benefit in response to onvansertib plus FOLFIRI/bevacizumab.
  • Price Action: CRDF shares are up 6.55% at $3.09 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CarePre-Market OutlookMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!